Merck demonstrated resilience by maintaining its full-year guidance despite a 3% revenue decline driven by foreign exchange and some product setbacks. Management's confident tone regarding the ongoing merger with Schering-Plough and growth in key pharmaceuticals like Singulair and Januvia provides optimism for sustained performance. These factors are likely to foster a positive sentiment in the short term.

[1]